Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27598749 | 0.98 | NOS1 (0.33) | NOS1 | |
| SCHEMBL52721 | 0.61 | SMN1; SMN2 (0.34) | — | |
| Bromide SCHEMBL9486332 | 0.61 | NOS1 (0.32) | NOS1 | |
| Bromide SCHEMBL9486340 | 0.60 | NOS1 (0.31) | NOS1 | |
| Bromide SCHEMBL16494365 | 0.60 | NOS1 (0.31) | NOS1 | |
| SCHEMBL2825385 | 0.59 | DPP4 (0.42) | — | |
| SCHEMBL2496995 | 0.59 | NOS1 (0.38) | NOS1 | |
| SCHEMBL27839525 | 0.57 | NOS1 (0.32) | NOS1 | |
| SCHEMBL27696174 | 0.56 | NOS1 (0.34) | NOS1 | |
| SCHEMBL14196470 | 0.55 | ALDH1A1 (0.41) | NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390490-B2 | Sphingolipid-based selenium compounds, methods for their preparation, and pharmaceutical uses thereof, including as antitumor agents | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2025-08-19 | — | — | US | disclosed |
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| US-20220288109-A1 | SPHINGOLIPID-BASED SELENIUM COMPOUNDS, METHODS FOR THEIR PREPARATION, AND PHARMACEUTICAL USES THEREOF, INCLUDING AS ANTITUMOR AGENTS | MUSC FOUND FOR RES DEV (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4021892-A1 | SPHINGOLIPID-BASED SELENIUM COMPOUNDS, METHODS FOR THEIR PREPARATION, AND PHARMACEUTICAL USES THEREOF, INCLUDING AS ANTITUMOR AGENTS | Musc Foundation for Research Development (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114073668-A | Semi-solid preparation | 广州朗圣药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| WO-2021236818-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021041825-A1 | SPHINGOLIPID-BASED SELENIUM COMPOUNDS, METHODS FOR THEIR PREPARATION, AND PHARMACEUTICAL USES THEREOF, INCLUDING AS ANTITUMOR AGENTS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10661095-B2 | Photodynamic therapy for use in treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-05-26 | — | — | US | disclosed |
| CN-110305188-B | New compound for preventing HIV infection and preparation method thereof | 广州朗圣药业有限公司 | 2020-03-13 | — | — | CN | disclosed |
| US-20190015678-A1 | PHOTODYNAMIC THERAPY FOR USE IN TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-01-17 | — | — | US | disclosed |
| WO-2012127012-A1 | BIPHENYL TRICYCLIC QUINAZOLINE COMPOUNDS | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2012-09-27 | — | — | WO | disclosed |
| US-20120015023-A1 | Treatment of tumors prostate with arsonoliposomes | CELLVAX S.A. (FR) | 2012-01-19 | — | — | US | disclosed |
| US-20110008302-A1 | Compositions and methods for immortalizing cells and screening for anti-cancer agents | TSICHLIS PHILIP N | 2011-01-13 | — | — | US | disclosed |
| CN-100350902-C | Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan | KOTOSUGI INC (JP) | 2007-11-28 | — | — | CN | disclosed |
| US-7271260-B2 | 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-09-18 | — | — | US | disclosed |
| US-20050197351-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2005-09-08 | — | — | US | disclosed |
| CN-1665493-A | Hypoglycemic agent, hepatoprotective agent, and anticancer agent containing xylan derived from Taxus chinensis | KOTOSUGI INC (JP) | 2005-09-07 | — | — | CN | disclosed |
| EP-1568695-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | Korea Institute of Science and Technology (KR) | 2005-08-31 | — | — | EP | disclosed |
| EP-1166781-A1 | PROTEASOME INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-20010046491-A1 | Tumor radiosensitization with mutant thymidine kinase in combination with a prodrug | VALERIE KRISTOFFER C (US) | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390490-B2 | Sphingolipid-based selenium compounds, methods for their preparation, and pharmaceutical uses thereof, including as antitumor agents | SGMS1, SGMS2, SELENOI | NOS1 3971/4885 |
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | TFAM, NDUFAF1, NDUFV1 | NOS1 2439/4885 |
| US-20220288109-A1 | SPHINGOLIPID-BASED SELENIUM COMPOUNDS, METHODS FOR THEIR PREPARATION, AND PHARMACEUTICAL USES THEREOF, INCLUDING AS ANTITUMOR AGENTS | SGMS1, SGMS2, SELENOI | NOS1 4141/4885 |
| US-20050197351-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | CACNA1I, CACNA1G, CACNA1H | NOS1 2056/4885 |
| US-20120015023-A1 | Treatment of tumors prostate with arsonoliposomes | ACP3, BPHL, AR | NOS1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.